Category: 1209459-32-4

Luo, Zhi et al. published their patent in 2018 |CAS: 1209459-32-4

The Article related to haloaryloxymethylallylamine preparation ssao inhibitor treatment nonalc steatohepatitis, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Ethers, Sulfides, and The Corresponding Onium Compounds and other aspects.SDS of cas: 1209459-32-4

On December 27, 2018, Luo, Zhi; Li, Xiaolin; Yang, Yaxun; Yang, Lele; Li, Peng; He, Haiying; Li, Jian; Chen, Shuhui published a patent.SDS of cas: 1209459-32-4 The title of the patent was Preparation of 3-halo-2-(aryloxymethyl)allylamine derivatives useful as semicarbazide-sensitive amine oxidase (SSAO) inhibitors for the treatment of nonalcohol steatohepatitis. And the patent contained the following:

The invention relates to 3-halo-2-(aryloxymethyl)allylamine derivatives of formula I, method for their preparation and their use as semicarbazide-sensitive amine oxidase (SSAO) inhibitors for the treatment of nonalc. steatohepatitis. Compounds of formula I, wherein one of R4 and R5 is H and another is F, Cl, Br and I; R1 is H, halo, CO2H, (un)substituted Ph, etc.; L1 is a bond, SO2O, NHCO, NH, etc.; n is 0 to 3; R is H, F, Cl, CONH2, etc.; ring A is R substituted 5- to 6-membered heterocycle, Ph and 5- to 9-membered heteroaryl, and their pharmaceutically acceptable salts, are claimed. Example compound II was prepared via a multistep procedure (procedure given). All the invention compounds were evaluated for their VAP-1/SSAO inhibitory activity. From the assay, it was determined that example compound II exhibited IC50 value of 0.3 nM towards VAP-1/SSAO. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).SDS of cas: 1209459-32-4

The Article related to haloaryloxymethylallylamine preparation ssao inhibitor treatment nonalc steatohepatitis, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Ethers, Sulfides, and The Corresponding Onium Compounds and other aspects.SDS of cas: 1209459-32-4

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Woodring, Jennifer L. et al. published their research in European Journal of Medicinal Chemistry in 2017 |CAS: 1209459-32-4

The Article related to anilinoquinazoline trypanosome inhibitor antimalarial malaria trypanosomiasis trypanosomicide, human african trypanosomiasis, leishmania major, neglected tropical disease, plasmodium falciparum, target class repurposing, trypanosoma brucei, trypanosoma cruzi and other aspects.COA of Formula: C8H10BrN3O

On December 1, 2017, Woodring, Jennifer L.; Bachovchin, Kelly A.; Brady, Kimberly G.; Gallerstein, Mitchell F.; Erath, Jessey; Tanghe, Scott; Leed, Susan E.; Rodriguez, Ana; Mensa-Wilmot, Kojo; Sciotti, Richard J.; Pollastri, Michael P. published an article.COA of Formula: C8H10BrN3O The title of the article was Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation. And the article contained the following:

Human African trypanosomiasis (HAT) is a deadly disease in need of new chemotherapeutics that can cross into the central nervous system. The authors previously reported the discovery of (NEU-617), a small mol. with activity against T. brucei bloodstream proliferation. Further optimization of NEU-617 to improve the physicochem. properties (LogP, LLE, [1], and MPO score) [2] have led us to twelve sub-micromolar compounds, most importantly the headgroup variants I and II, and the linker variant III. Although these 3 compounds had reduced potency compared to NEU-617, they all had improved LogP, LLE and MPO scores. Cross-screening these analogs against other protozoan parasites uncovered IV with potent activity towards T. brucei, T. cruzi and L. major, while four others compounds showed activity towards P. falciparum D6. This reinforces the effectiveness of lead repurposing for the discovery of new protozoan disease therapeutics. The experimental process involved the reaction of 4-(2-Bromopyrimidin-4-yl)morpholine(cas: 1209459-32-4).COA of Formula: C8H10BrN3O

The Article related to anilinoquinazoline trypanosome inhibitor antimalarial malaria trypanosomiasis trypanosomicide, human african trypanosomiasis, leishmania major, neglected tropical disease, plasmodium falciparum, target class repurposing, trypanosoma brucei, trypanosoma cruzi and other aspects.COA of Formula: C8H10BrN3O

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Extended knowledge of 1209459-32-4

If you are interested in these compounds, you can also browse my other articles.Thank you for taking the time to read this article. I hope you enjoyed it, 1209459-32-4, 4-(2-Bromopyrimidin-4-yl)morpholine.

Researchers who often do experiments know that organic synthesis is a process of preparing more complex target molecules from simple raw materials through one or more chemical reactions. Generally, it requires fewer steps,and cheap raw materials. 1209459-32-4, name is 4-(2-Bromopyrimidin-4-yl)morpholine. A new synthetic method of this compound is introduced below., category: pyrimidines

To a microwave vi charged with (S)-2-(3,4-dimethylpiperazin-l-yl)-4-fluoro-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)aniline (0.143, 0.410 mmol), 4-(2-bromopyrimidin-4-yl)morpholine (0.150 g ,0.615 mmol), K3P04 (0.174 g, 0.819 mmol) was added dioxane (2 ml) and water (2 ml) and the vial was flushed with nitrogen. Bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (0.0087 g, 0.030 mmol) was added, the vial was sealed, and the mixture heated in a microwave reactor to 110C for 30 minutes. The crude mixture was concentrated onto celite and purified using reverse phase silca gel column chromatography (Water: AcCN gradient 0-100%). The product was dried under vacuum to give the title compound as a brown solid (0.097 g, 61 %); LCMS [M + H]+ 387

If you are interested in these compounds, you can also browse my other articles.Thank you for taking the time to read this article. I hope you enjoyed it, 1209459-32-4, 4-(2-Bromopyrimidin-4-yl)morpholine.

Reference:
Patent; ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR); AL-AWAR, Rima; ZEPEDA-VELAZQUEZ, Carlos Armando; PODA, Gennady; ISAAC, Methvin; UEHLING, David; WILSON, Brian; JOSEPH, Babu; LIU, Yong; SUBRAMANIAN, Pandiaraju; MAMAI, Ahmed; PRAKESCH, Michael; STILLE, Julia Kathleen; (1053 pag.)WO2017/147700; (2017); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Extended knowledge of 4-(2-Bromopyrimidin-4-yl)morpholine

According to the analysis of related databases, 1209459-32-4, the application of this compound in the production field has become more and more popular.

Electric Literature of 1209459-32-4, Adding some certain compound to certain chemical reactions, such as: 1209459-32-4, name is 4-(2-Bromopyrimidin-4-yl)morpholine,molecular formula is C8H10BrN3O, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound 1209459-32-4.

To a microwave tube was added N-isopropyl-3-(trimethylstannyl)-1-trityl-1H-pyrazolo[4,3-c]pyridin-4-amine (200 mg, 0.344 mmol), 4-(2-bromopyrimidin-4-yl)morpholine (168 mg, 0.688 mmol), LiCl (58.0 mg, 1.38 mmol), CuI (13.0 mg, 0.0688 mmol), Pd(PPh3)4 (40.0 mg, 0.0344 mmol), and THF (3.0 mL). After three cycles of vacuum/argon flash, the reaction mixture was heated at 100 C. for 1 hour under microwave irradiation. After cooling down to room temperature, the mixture was filtered via Celite. The filtrate was concentrated under reduced pressure. The residue was purified by prep-TLC eluting with petroleum ether/ethyl acetate (1:2) to afford the title compound as a yellow solid (25 mg, 13%).

According to the analysis of related databases, 1209459-32-4, the application of this compound in the production field has become more and more popular.

Reference:
Patent; Genentech, Inc.; Chan, Bryan; Estrada, Anthony; Shore, Daniel; Sweeney, Zachary; US2014/288043; (2014); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia